AR and prostate carcinoma: Collectively, these findings suggest that targeting the AR NTD with ATRA and ralaniten may induce G1 arrest and senescence in prostate cancer cells that express AR-Vs, by a mechanism involving the Skp2/p27Kip1 pathway and Rb inactivation but not requiring p16INK4A.